Kineta Inc. Stock Analysis KANT

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. The company is headquartered in Mercer Island, Washington and currently employs 4 full-time employees. The company went IPO on 2016-02-11. The firm has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. The innate immune target VISTA is highly expressed in many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, ovarian cancer, renal cell carcinoma, and head and neck squamous cell carcinoma. The firm is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.